GSK and Relation Therapeutics announce $110 million AI drug discovery partnership

Jul 30, 2026

Relation Therapeutics and GSK announce a research collaboration worth up to $110 million to generate human cellular datasets and train AI models, including the MORGAN platform, for drug target identification. The deal builds on a prior partnership targeting fibrotic diseases and osteoarthritis. GSK is expanding its artificial intelligence use and increasing research and development investments to boost its drug pipeline efficiency.

GSK-Relation AI drug discovery partnership

▪The collaboration between Relation Therapeutics and GSK builds on an earlier partnership focused on fibrotic diseases and osteoarthritis.
▪Relation Therapeutics entered a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train artificial intelligence models.

AI-driven drug target identification

▪Relation Therapeutics will generate large-scale datasets showing how human cells respond to genetic and drug interventions to identify potential new drug targets.
▪The datasets generated by Relation Therapeutics will be used to train artificial intelligence foundation models, including the MORGAN platform.

GSK R&D investment strategy

▪GSK is increasing investment in research and development to strengthen the company's drug pipeline.
▪GSK is expanding the use of artificial intelligence to improve the efficiency and success rate of drug discovery.